Standard BioTools Inc. (NASDAQ:LAB - Get Free Report) SVP Sean Mackay sold 13,217 shares of the firm's stock in a transaction dated Friday, May 23rd. The stock was sold at an average price of $0.94, for a total transaction of $12,423.98. Following the sale, the senior vice president now owns 843,076 shares of the company's stock, valued at approximately $792,491.44. The trade was a 1.54% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.
Sean Mackay also recently made the following trade(s):
- On Thursday, May 22nd, Sean Mackay sold 12,536 shares of Standard BioTools stock. The stock was sold at an average price of $1.00, for a total transaction of $12,536.00.
- On Wednesday, May 21st, Sean Mackay sold 12,838 shares of Standard BioTools stock. The shares were sold at an average price of $1.03, for a total transaction of $13,223.14.
Standard BioTools Trading Down 2.4%
Shares of Standard BioTools stock traded down $0.03 during trading on Friday, reaching $1.04. The company's stock had a trading volume of 1,145,709 shares, compared to its average volume of 2,130,774. The company has a 50-day moving average price of $1.11 and a two-hundred day moving average price of $1.42. The firm has a market cap of $393.12 million, a PE ratio of -1.46 and a beta of 1.80. Standard BioTools Inc. has a fifty-two week low of $0.92 and a fifty-two week high of $2.60.
Wall Street Analyst Weigh In
Separately, KeyCorp cut shares of Standard BioTools from an "overweight" rating to a "sector weight" rating in a report on Thursday, February 27th.
Check Out Our Latest Stock Report on LAB
Hedge Funds Weigh In On Standard BioTools
A number of institutional investors have recently modified their holdings of the business. Jump Financial LLC purchased a new position in Standard BioTools during the 1st quarter worth $26,000. Takeda Pharmaceutical Co. Ltd. purchased a new position in Standard BioTools during the 4th quarter worth $29,000. IQ EQ FUND MANAGEMENT IRELAND Ltd raised its position in Standard BioTools by 115.6% during the 1st quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd now owns 27,119 shares of the company's stock worth $29,000 after buying an additional 14,541 shares during the last quarter. Two Sigma Securities LLC purchased a new position in Standard BioTools during the 4th quarter worth $30,000. Finally, CWM LLC raised its position in Standard BioTools by 101.8% during the 1st quarter. CWM LLC now owns 29,705 shares of the company's stock worth $32,000 after buying an additional 14,984 shares during the last quarter. 53.74% of the stock is owned by institutional investors and hedge funds.
Standard BioTools Company Profile
(
Get Free Report)
Standard BioTools Inc, together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument.
Further Reading
Before you consider Standard BioTools, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Standard BioTools wasn't on the list.
While Standard BioTools currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
